Aptevo Navigates Pre-Revenue Stage with Aggressive Capital Raises

TL;DR

**APVO is burning cash and constantly diluting shareholders to stay afloat; it's a high-risk bet on future pipeline success.**

AI Summary

Aptevo Therapeutics Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was not explicitly stated with a dollar amount in the provided data, but the focus remains on financing operations. A significant business change includes the April 4, 2025 Registered Direct Offering, which involved the sale of common stock and warrants. The company also entered into an At-The-Market Offering on April 28, 2025, to raise capital. Key risks include the ongoing need for additional financing to fund operations and clinical development, as evidenced by the various equity offerings. The strategic outlook is centered on advancing its pipeline, which is heavily reliant on successful capital raises and managing its cash burn. The company's ability to continue as a going concern is dependent on its ability to obtain sufficient funding.

Why It Matters

Aptevo's aggressive capital raises, including the April 4, 2025 Registered Direct Offering and the April 28, 2025 At-The-Market Offering, are critical for its survival as a pre-revenue biotech. For investors, this signals high dilution risk but also the company's commitment to funding its pipeline. Employees face job security tied directly to successful financing rounds. Customers, primarily future patients, depend on these funds to advance potential therapies. In the competitive biotech landscape, Aptevo's ability to secure capital directly impacts its capacity to compete with larger, more established pharmaceutical companies.

Risk Assessment

Risk Level: high — Aptevo Therapeutics Inc. is a pre-revenue company, as evidenced by zero revenue for the three and six months ended June 30, 2025. The company's reliance on frequent equity offerings, such as the April 4, 2025 Registered Direct Offering and the April 28, 2025 At-The-Market Offering, to fund operations indicates a high burn rate and significant dilution risk for existing shareholders. This continuous need for capital, without a clear path to profitability, places it in a high-risk category.

Analyst Insight

Investors should approach APVO with extreme caution, recognizing the significant dilution risk and the company's pre-revenue status. Consider this a highly speculative investment, suitable only for those with a high-risk tolerance and a long-term view on potential drug development success. Monitor future capital raises and clinical trial progress closely.

Financial Highlights

revenue

$0

revenue Growth

0.00%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• 2025-04-04 — Registered Direct Offering Date (date of a key capital raise)
• 2025-04-28 — At-The-Market Offering Date (date of another capital raise initiation)
• 2025-06-30 — Conformed Period of Report (end date of the financial reporting period)
• 2025-08-11 — Filed As Of Date (date the 10-Q was filed)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — filer of the 10-Q
• 0001671584 (regulator) — Central Index Key (CIK) for Aptevo Therapeutics Inc.
• April 4, 2025 Registered Direct Offering (event) — significant capital raise event
• April 28, 2025 At-The-Market Offering (event) — capital raise mechanism
• June 30, 2025 (date) — end of the reporting period
• November 30, 2025 (date) — expiration date for certain warrants
• November 30, 2028 (date) — expiration date for certain warrants
• April 30, 2029 (date) — expiration date for certain warrants
• August 31, 2029 (date) — expiration date for certain warrants
• December 31, 2029 (date) — expiration date for certain warrants

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company's ability to continue as a going concern is highly dependent on its ability to secure additional funding. This is evidenced by multiple equity offerings, including a Registered Direct Offering on April 4, 2025, and an At-The-Market Offering initiated on April 28, 2025, to fund operations and clinical development.
• Pre-Commercial Stage Operations [high — operational]: Aptevo Therapeutics Inc. reported no revenue for the three and six months ended June 30, 2025. This pre-commercial status means the company relies entirely on external financing to fund its research, development, and operational activities.
• Cash Burn Management [high — financial]: The company's strategic outlook is centered on advancing its pipeline, which is heavily reliant on successful capital raises and effectively managing its cash burn rate. Without consistent funding, progress on pipeline development is at risk.

Industry Context

Aptevo Therapeutics operates in the highly competitive biopharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies in this sector often rely on external financing to advance their drug candidates through clinical trials and towards commercialization.

Regulatory Implications

As a biopharmaceutical company, Aptevo is subject to rigorous oversight from regulatory bodies like the FDA. Successful navigation of clinical trials and regulatory approval processes are critical for pipeline advancement. Delays or failures in these areas can significantly impact the company's financial health and strategic trajectory.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Evaluate pipeline progress and clinical trial updates.
3. Assess the dilution impact of equity offerings.

Key Dates

• 2025-04-04: Registered Direct Offering — A significant capital raise event involving the sale of common stock and warrants to fund operations and development.
• 2025-04-28: At-The-Market Offering Initiation — Another key initiative to raise capital, demonstrating the ongoing need for financing to support the company's activities.
• 2025-06-30: Conformed Period of Report — The end date of the financial reporting period covered by this 10-Q filing.
• 2025-08-11: Filed As Of Date — The date this 10-Q filing was officially submitted to the SEC.

Glossary

Registered Direct Offering

A type of securities offering where a company sells stock directly to a select group of institutional investors, often with pre-negotiated terms. (A primary method Aptevo Therapeutics is using to raise capital for its operations and development.)

At-The-Market Offering (ATM)

A method for a company to sell its stock in the open market over a period of time, typically through an intermediary, allowing for flexible capital raising. (Indicates Aptevo's strategy to continuously access capital as needed to fund its ongoing operations.)

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (Aptevo's ability to continue as a going concern is explicitly stated as dependent on obtaining sufficient funding, highlighting a significant financial risk.)

Pre-commercial Stage

A phase in a biotechnology or pharmaceutical company's lifecycle where it has not yet generated revenue from product sales, focusing instead on research and development. (Explains why Aptevo Therapeutics has zero revenue and relies on financing.)

Year-Over-Year Comparison

For the three and six months ended June 30, 2025, Aptevo Therapeutics reported $0 in revenue, consistent with the prior year periods, reinforcing its pre-commercial status. The company has continued its strategy of raising capital through equity offerings, with a Registered Direct Offering in April 2025 and an At-The-Market offering initiated the same month. No new significant risks were detailed beyond the ongoing reliance on financing and the inherent challenges of clinical development, which remain high severity.

Key Financial Figures

• $0.001 — nge on Which Registered Common Stock, $0.001 par value per share APVO The Nasdaq

Filing Documents

• apvo-20250630.htm (10-Q) — 1810KB
• apvo-ex31_1.htm (EX-31.1) — 17KB
• apvo-ex31_2.htm (EX-31.2) — 17KB
• apvo-ex32_1.htm (EX-32.1) — 10KB
• apvo-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-106247.txt ( ) — 6894KB
• apvo-20250630.xsd (EX-101.SCH) — 1206KB
• apvo-20250630_htm.xml (XML) — 891KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 56 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 58

Signatures

Signatures 59 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Aptevo," and "the Company" refer to Aptevo Therapeutics Inc. and, where appropriate, its consolidated subsidiaries. 2

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. Aptevo Therapeutics Inc. CONDENSED CONSOLIDATED B ALANCE SHEETS (in thousands, except share and per share amounts, unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 9,410 $ 8,714 Prepaid expenses 1,589 1,689 Other current assets 82 256 Total current assets 11,081 10,659 Property and equipment, net 432 543 Operating lease right-of-use asset 4,111 4,389 Total assets $ 15,624 $ 15,591 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and other accrued liabilities $ 2,903 $ 3,053 Accrued compensation 1,040 1,856 Other current liabilities 948 1,298 Total current liabilities 4,891 6,207 Operating lease liability 4,209 4,629 Total liabilities 9,100 10,836 Stockholders' equity: Preferred stock: $ 0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding — — Common stock: $ 0.001 par value; 500,000,000 shares authorized; 3,224,156 and 72,922 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 99 84 Additional paid-in capital 266,614 252,248 Accumulated deficit ( 260,189 ) ( 247,577 ) Total stockholders' equity 6,524 4,755 Total liabilities and stockholders' equity $ 15,624 $ 15,591 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Aptevo Therapeutics Inc. CONDENSED CONSOLIDATED STATEM ENTS OF OPERATIONS (in thousands, except share and per share amounts, unaudited) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ ( 3,328 ) $ ( 3,643 ) $ ( 6,961 ) $ ( 7,395 ) General and administrative ( 2,898 ) ( 2,381 ) ( 5,745 ) ( 5,612 ) Loss from operations ( 6,226 )

View Full Filing

View this 10-Q filing on SEC EDGAR